CuriRx Inc
CuriRx, Inc. is a Massachusetts-based Contract Research, Development, and Manufacturing Organization (CRDMO) dedicated to redefining healthcare norms through innovative drug development solutions. The company emphasizes quality, agility, and responsibility, fostering a diverse and collaborative work environment. CuriRx offers a broad range of services including formulation, bioprocessing, analytical services, and support for complex biotherapeutic development, aiming to improve patient lives globally.
Industries
Nr. of Employees
small (1-50)
CuriRx Inc
Patents
Products
High-resolution mass spectrometry CMC analytics platform
Laboratory platform centered on high-resolution mass spectrometry and orthogonal analytical techniques for characterization of complex biotherapeutics and CMC support.
High-resolution mass spectrometry CMC analytics platform
Laboratory platform centered on high-resolution mass spectrometry and orthogonal analytical techniques for characterization of complex biotherapeutics and CMC support.
Services
Laboratory development of drug formulations and dosage forms including prefilled syringes, lyophilized products, and nanotechnology-enabled formulations; formulation studies to support clinical and commercial development.
End-to-end cell culture and purification services including cell line development, media/feed optimization, bioreactor process development, chromatography and filtration development, viral clearance strategy, and scale-up support.
Analytical method development, orthogonal characterization, phase-appropriate qualification and validation, and technology transfer to QC for both large and small molecule programs, from R&D through clinical release testing.
ICH-aligned stability study design and execution, release testing, quantification and verification, and long-term stability data generation to support development and commercialization.
High-resolution mass spectrometry-based characterization services for product and process-related impurities, structural attributes, and targeted proteomics to de-risk CMC characterization.
Laboratory development of drug formulations and dosage forms including prefilled syringes, lyophilized products, and nanotechnology-enabled formulations; formulation studies to support clinical and commercial development.
End-to-end cell culture and purification services including cell line development, media/feed optimization, bioreactor process development, chromatography and filtration development, viral clearance strategy, and scale-up support.
Analytical method development, orthogonal characterization, phase-appropriate qualification and validation, and technology transfer to QC for both large and small molecule programs, from R&D through clinical release testing.
ICH-aligned stability study design and execution, release testing, quantification and verification, and long-term stability data generation to support development and commercialization.
High-resolution mass spectrometry-based characterization services for product and process-related impurities, structural attributes, and targeted proteomics to de-risk CMC characterization.
Expertise Areas
- Bioprocessing development
- Formulation development
- Analytical development and CMC characterization
- Cell line and strain development
Key Technologies
- High-resolution mass spectrometry
- LC-MS/MS peptide mapping
- HPLC / SEC-HPLC
- Bioreactor-based fed-batch and continuous culture
News & Updates
CuriRx announced the launch of its Advanced Bioprocessing and Analytical Center, providing end-to-end support for biotherapeutic developers.
Join CuriRx for a lunch & learn about the CuriLytics® platform supporting de-risking CMC characterization.
CuriRx announced the launch of the CuriLytics® platform with high-resolution mass spectrometry for biotherapeutic development support.
A scientific publication on monoclonal antibody characterization.
CuriRx announced the launch of its Advanced Bioprocessing and Analytical Center, providing end-to-end support for biotherapeutic developers.
Join CuriRx for a lunch & learn about the CuriLytics® platform supporting de-risking CMC characterization.
CuriRx announced the launch of the CuriLytics® platform with high-resolution mass spectrometry for biotherapeutic development support.
A scientific publication on monoclonal antibody characterization.